In vivo, the combination of imvotamab and loncastuximab tesirine resulted in up to 100% TGI with several mice reaching complete responses, and enhanced overall survival compared to treatment with either single agent at study endpoint. IHC confirmed CD19 and CD20 expression in the Raji tumors on treatment...Our preclinical data indicate that combining imvotamab with loncastuximab tesirine results in potent anti-tumor activity and supports the rationale for testing this combination in the clinic.